What happens to a tumour when you take gravity away?
Forty days aboard the International Space Station produced a partial answer, published in March 2026. Patient-derived glioblastoma cultures grown in orbit came back with more uniform morphology than the matched ground controls. Beside that result sat a second one: microgravity raised the activity of cancer drivers such as ADAR1, the enzyme targeted by a drug now in a phase 1 trial.
TIMELINE: Orbital biomanufacturing
───────────────────────────────────────────────────────────────────────
2023 ───── 2024 ───── 2026-03 ───── 2026-06/07 ──── ◉ NOW ──── 2027
💊 🧫 📄 🖨️ 🧬 🚀
Ax-2: Ax-3 40-day First kidney Crew-13 Ax-5
first repeat GBM and liver stem-cell window,
cancer organoid organoid bioprinted tissues ESA MOU
drugs tests paper; in orbit; produced signed
on orbit ADAR1 link announced in orbit Sep 10
───────────────────────────────────────────────────────────────────────
Sources: Axiom Space · bioRxiv (Mar 2026) · Reuters (Jul 9, 2026)
· NASA (Oct 1, 2026) · ESA–Axiom (Sep 10, 2026)
Compiled from Axiom Space mission releases, the March 2026 bioRxiv preprint, Reuters reporting from ASCEND 2026 and NASA flight notes.
The organoid that changed the read-out
Axiom Space has flown Catriona Jamieson's experiments twice. Ax-2 carried the first cancer-drug tests ever performed off Earth in 2023. Ax-3 repeated the run a year later. Both sit inside ISSCOR, a NASA-funded centre built to keep stem cell research continuous on the station rather than tied to single payloads.
The molecule that came out of it is rebecsinib. It inhibits ADAR1, an RNA-editing enzyme. In the March 2026 preprint, ADAR1 activity showed up as one of the things microgravity turns up, which makes low Earth orbit a testing platform for the inhibitor itself. Aspera Biomedicines developed the compound; Jamieson's group at the University of California, San Diego, runs the programme. Axiom's release states the regulatory position without decoration: the FDA cleared it into clinical trials under an active IND, after orbital tests on Ax-2 and Ax-3.
That sentence is the milestone. An orbital experiment feeding a drug into human trials has a paper trail a regulator can point at.
The engineering detail sits in the growth numbers. Aerospace America's report from the ASCEND 2026 in-space manufacturing session put orbital organoid development at two to three times the pace of matched ground controls. Two to three times is the whole argument. A screen that absorbs a quarter on Earth compresses to weeks.
None of it produces an organ for a patient. The deliverable is a read-out: denser, faster tissue that tells a programme whether to spend the next $50 million.
The output is regulatory. Rebecsinib holds active IND status after orbital tests on Ax-2 and Ax-3 — an experiment-to-filing trail, not a demonstration.
The return is throughput. Orbital organoids run 2–3× the pace of ground controls, which is why the near-term business is screening, not transplantable tissue.
The capability is bolted to flight cadence. Every programme above depends on a launch window, and the ISS retires under NASA's 2030 plan.
Printing joined the same manifest
Auxilium Biotechnologies put its kidney and liver structures through bioprinting in orbit; the samples returned on SpaceX's CRS-34 splashdown on June 17, 2026, with results released July 9. NASA's Expedition 75 crew ran cartilage bioprinting on the station in mid-September. On October 1, SpaceX launched Crew-13 carrying hardware for stem-cell-derived tissue production, which NASA frames around disease modelling and drug testing.
Orbital organoid growth rate
Patient-derived tumour organoids developed two to three times faster in low Earth orbit than in matched ground incubators. · Aerospace America, ASCEND 2026
Three programmes, three tissue types, one dependency: flight slots. A printer that runs once per resupply cycle cannot serve a pipeline that wants monthly screens. Cadence, not printer resolution, sets the ceiling.
Watch for that distinction in company language. Auxilium sells a manufacturing claim. NASA sells a research claim. Axiom sells access. All three are renting the same rack space.
Who owns the rack space
Follow the manifests and four roles separate cleanly. Axiom Space sells crew seats and lab volume; its memorandum of understanding with ESA on September 10 is a demand signal from a space agency, which reads differently from a startup pilot. Starlab and Vast sell pressurised volume for the period after the ISS. Auxilium and BioOrbit sell the instruments that ride inside: printers, culture hardware, consumables that make a payload repeatable instead of a one-off. Redwire and the ISS National Lab sell the integration step that turns a proposal into a manifested slot.
ISS National Lab channels part of that work through its Orbital Edge Accelerator, aimed at companies building hardware for the orbital economy. BioOrbit's £9.8 million seed round funds the same equipment category from the other direction: culture systems designed for microgravity rather than adapted from a ground incubator.
The distinction matters when a programme drafts a 2027 budget. Seats and volume are booked years out. Instruments can be bought this year. A team that secures hardware without a slot owns an expensive paperweight; a team that books a slot without hardware waits for the next resupply.
The line item the ISS retires with
Hardware is the visible part of the transition. Axiom signed a memorandum of understanding with ESA on September 10, 2026 to widen European access to low Earth orbit, and its Ax-5 mission was selected on January 30, 2026 for a 2027 flight. Starlab and Vast are building stations. BioOrbit closed a £9.8 million seed round to industrialise cell culture hardware. Varda and United Therapeutics, Redwire and ExesaLibero have already paired payload makers with commercial platforms.
The question for a biotech programme budgeting 2027 work is narrow. Which station carries the assay, at what flight rate, under whose data package?
What still has to be true
Regulators accept orbital read-outs repeatedly. One molecule cleared under an active IND after Ax-2 and Ax-3 tests is a precedent. A second one is a pattern.
Cost per sample beats the counter. Two to three times faster loses to ten times more expensive.
ISS National Lab channels money through its Orbital Edge Accelerator to answer exactly those three. If the answers arrive before the station's retirement date, orbital screening leaves as a service. If they arrive after, the work restarts on Starlab or Axiom Station with fresh qualification.
Where the pipeline sits today
One IND. Two bioprinted organ types returned to Earth. Crew-13 delivering tissue production hardware in October. The chain runs from microgravity observation to a filing regulators signed.
Ax-5 flies in 2027. If Jamieson's organoids ride it, the orbital screen becomes a repeat service with a schedule. If not, the 2026 results stay a pair of experiments that happened to share a rack.